Vaccines against human papillomavirus: perspectives for controlling cervical cancer

References

• Ullmann EV. On the aetiology of the laryngeal papilloma. Acta Oto-laryngol.5, 317–334 (1923).
   Google Scholar
• M’Fadyan J, Hobday F. Note on the experimental “transmission of warts in the dog”. J. Comp. Pathol. Ther.11, 341–344 (1898).
   Google Scholar
• Ciuffo G. Innesto positive con filtrato di verruca vulgare. Giorn. Ital. Mal. Venereol.48, 12 (1907).
   Google Scholar
• Rous P. A sarcoma of the fowl transmissible by agent separable from tumor cells. J. Exp Med.13, 397–411 (1911).
   PubMedGoogle Scholar
• National Toxicology Program DHHS. The report on carcinogens. Federal Register, DC, USA (2005).
   Google Scholar
• IARC WG. IARC monographs on the evaluation of carcinogenic risks to humans: human papillomaviruses. International Agency for Research on Cancer, Lyon, France (1995).
   Google Scholar
• zur Hausen H. Papillomavirus infections – a major cause of human cancers. Biochim. et Biophys. Acta1288(2), F55–F78 (1996).
   PubMed Web of Science ®Google Scholar
• Spence A, Franco E, Ferenczy A. The role of human papillomaviruses in cancer: evidence to date. Am. J. Cancer4, 49–64 (2005).
   Google Scholar
• Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Path.189(1), 12–19 (1999).
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine24(Suppl. 3), S11–S25 (2006).
   Web of Science ®Google Scholar
• Chan SY, Ho L, Ong CK et al. Molecular variants of human papillomavirus type 16 from four continents suggest ancient pandemic spread of the virus and its coevolution with humankind. J. Virol.66(4), 2057–2066 (1992).
   PubMedGoogle Scholar
• Yamada T, Manos MM, Peto J et al. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J. Virol.71(3), 2463–2472 (1997).
   PubMed Web of Science ®Google Scholar
• Lizano M, Garcia-Carranca A. Molecular variants of human papillomaviruses types 16, 18, and 45 in tumors of the uterine cervix in Mexico. Gaceta Medica de Mexico133(Suppl. 1), 43–48 (1997).
   PubMedGoogle Scholar
• Berumen J, Ordonez RM, Lazcano E et al. Asian–American variants of human papillomavirus 16 and risk for cervical cancer: a case–control study. J. Natl Cancer Inst.93(17), 1325–1330 (2001).
   PubMedGoogle Scholar
• Papanicolaou GN. A survey of the actualities and potentialities of exfoliative cytology in cancer diagnosis. Ann. Intern. Med.31(4), 661–674 (1949).
   PubMedGoogle Scholar
• Cuzick J. Human papillomavirus testing for primary cervical cancer screening. JAMA283(1), 108–109 (2000).
   PubMedGoogle Scholar
• Cuzick J, Mayrand MH, Ronco G, Snijders P, Wardle J. Chapter 10: new dimensions in cervical cancer screening. Vaccine24(Suppl. 3), S90–S97 (2006).
   PubMed Web of Science ®Google Scholar
• Cox T, Cuzick J. HPV DNA testing in cervical cancer screening: from evidence to policies. Gynecologic Oncol.103(1), 8–11 (2006).
   PubMedGoogle Scholar
• Munoz N, Bosch FX, de Sanjose S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med.348(6), 518–527 (2003).
   PubMed Web of Science ®Google Scholar
• zur Hausen H. Proliferation-inducing viruses in non-permissive systems as possible causes of human cancers. Lancet357(9253), 381–384 (2001).
   PubMedGoogle Scholar
• Munger K, Baldwin A, Edwards KM et al. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol.78(21), 11451–11460 (2004).
   PubMed Web of Science ®Google Scholar
• Schlecht NF, Platt RW, Duarte-Franco E et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J. Natl Cancer Inst.95(17), 1336–1343 (2003).
   PubMedGoogle Scholar
• de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology324(1), 17–27 (2004).
   PubMed Web of Science ®Google Scholar
• Munoz N, Franceschi S, Bosetti C et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case–control study. Lancet359(9312), 1093–1101 (2002).
   PubMed Web of Science ®Google Scholar
• Vaccarella S, Franceschi S, Herrero R et al. Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol. Biomarkers Prev.15(2), 326–333 (2006).
   PubMed Web of Science ®Google Scholar
• Mantovani F, Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene20(54), 7874–7887 (2001).
   PubMed Web of Science ®Google Scholar
• Castle PE, Zemlo TR, Burk RD et al. Cervical HPV DNA detection as a predictor of a recurrent SIL diagnosis among untreated women. J. Low. Genit. Tract Dis.5(3), 138–143 (2001).
   PubMedGoogle Scholar
• Schiffman MH, Brinton LA. The epidemiology of cervical carcinogenesis. Cancer76(10 Suppl.), 1888–1901 (1995).
   PubMed Web of Science ®Google Scholar
• Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am. J. Epidemiol.151(12), 1158–1171 (2000).
   PubMed Web of Science ®Google Scholar
• Manhart LE, Holmes KK, Koutsky LA et al. Human papillomavirus infection among sexually active young women in the United States: implications for developing a vaccination strategy. Sex. Transmi. Dis.33(8), 502–508 (2006).
   PubMed Web of Science ®Google Scholar
• Peh WL, Middleton K, Christensen N et al. Life cycle heterogeneity in animal models of human papillomavirus-associated disease. J. Virol.76(20), 10401–10416 (2002).
   PubMed Web of Science ®Google Scholar
• Stanley M, Lowy DR, Frazer I. Chapter 12: prophylactic HPV vaccines: underlying mechanisms. Vaccine24(Suppl. 3), S106–S113 (2006).
   PubMed Web of Science ®Google Scholar
• Coleman N, Birley HD, Renton AM et al. Immunological events in regressing genital warts. Am. J. Clin. Pathol.102(6), 768–774 (1994).
   PubMed Web of Science ®Google Scholar
• Scott M, Stites DP, Moscicki AB. Th1 cytokine patterns in cervical human papillomavirus infection. Clin. Diagn. Lab. Immunol.6(5), 751–755 (1999).
   PubMedGoogle Scholar
• David AL, Taylor GM, Gokhale D, Aplin JD, Seif MW, Tindall VR. HLA-DQB1*03 and cervical intraepithelial neoplasia type III. Lancet340(8810), 52 (1992).
   PubMedGoogle Scholar
• Apple RJ, Becker TM, Wheeler CM, Erlich HA. Comparison of human leukocyte antigen DR–DQ disease associations found with cervical dysplasia and invasive cervical carcinoma. J. Natl Cancer Inst.87(6), 427–436 (1995).
   PubMed Web of Science ®Google Scholar
• Vandenvelde C, De Foor M, van Beers D. HLA-DOB1*03 and cervical intraepithelial neoplasia grades I–III. Lancet341(8842), 442 (1993).
   PubMedGoogle Scholar
• Hildesheim A, Schiffman M, Scott DR et al. Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case–control study conducted in the United States. Cancer Epidemiol. Biomarkers Prev.7(11), 1035–1041 (1998).
   PubMedGoogle Scholar
• Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nat. Genet.6(2), 157–162 (1994).
   PubMed Web of Science ®Google Scholar
• Maciag PC, Schlecht NF, Souza PS, Rohan TE, Franco EL, Villa LL. Polymorphisms of the human leukocyte antigen DRB1 and DQB1 genes and the natural history of human papillomavirus infection. J. Infect. Dis.186(2), 164–172 (2002).
   PubMed Web of Science ®Google Scholar
• Franco EL, Ferenczy A. Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination. Future Oncol.3(3), 319–327 (2007).
   PubMedGoogle Scholar
• Schiffman M, Castle PE. The promise of global cervical-cancer prevention. N. Engl. J. Med.353(20), 2101–2104 (2005).
   PubMed Web of Science ®Google Scholar
• Shastri SS, Dinshaw K, Amin G et al. Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India. Bull. World Health Organ.83(3), 186–194 (2005).
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S. A critical assessment of screening methods for cervical neoplasia. Int. J. Gynaecol. Obstet.89(Suppl. 2), S4–S12 (2005).
   PubMed Web of Science ®Google Scholar
• Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD et al. Cost–effectiveness of cervical-cancer screening in five developing countries. N. Engl. J. Med.353(20), 2158–2168 (2005).
   PubMed Web of Science ®Google Scholar
• Goldhaber-Fiebert JD, Goldie SJ. Estimating the cost of cervical cancer screening in five developing countries. Cost Eff. Resour. Alloc.4, 13 (2006).
   PubMedGoogle Scholar
• Wright TC, Bosch FX, Franco EL et al. Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine24(Suppl. 3), S251–S261 (2006).
   Web of Science ®Google Scholar
• Frazer I. Vaccines for papillomavirus infection. Virus Res.89(2), 271–274 (2002).
   PubMed Web of Science ®Google Scholar
• Flores ER, Allen-Hoffmann BL, Lee D, Sattler CA, Lambert PF. Establishment of the human papillomavirus type 16 (HPV–16) life cycle in an immortalized human foreskin keratinocyte cell line. Virology262(2), 344–354 (1999).
   PubMed Web of Science ®Google Scholar
• McLaughlin-Drubin ME, Meyers C. Propagation of infectious, high-risk HPV in organotypic “raft” culture. Methods Mol. Med.119, 171–186 (2005).
   PubMedGoogle Scholar
• Fang L, Meyers C, Budgeon LR, Howett MK. Induction of productive human papillomavirus type 11 life cycle in epithelial cells grown in organotypic raft cultures. Virology347(1), 28–35 (2006).
   PubMed Web of Science ®Google Scholar
• Thomas JT, Oh ST, Terhune SS, Laimins LA. Cellular changes induced by low-risk human papillomavirus type 11 in keratinocytes that stably maintain viral episomes. J. Virol.75(16), 7564–7571 (2001).
   PubMed Web of Science ®Google Scholar
• Jenkins AL, Lang CM, Budgeon LR et al. Mucosally-derived HPV-40 can infect both human genital foreskin and cutaneous hand skin tissues grafted into athymic mice. Virus Res.93(1), 109–114 (2003).
   PubMedGoogle Scholar
• Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology185(1), 251–257 (1991).
   PubMed Web of Science ®Google Scholar
• Breitburd F, Kirnbauer R, Hubbert NL et al. Immunization with virus like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol.69(6), 3959–3963 (1995).
   PubMed Web of Science ®Google Scholar
• Suzich JA, Ghim SJ, Palmer-Hill FJ et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl Acad. Sci. USA92(25), 11553–11557 (1995).
   PubMed Web of Science ®Google Scholar
• Kirnbauer R, Chandrachud LM, O’Neil BW et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology219(1), 37–44 (1996).
   PubMed Web of Science ®Google Scholar
• Harro CD, Pang YY, Roden RB et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl Cancer Inst.93(4), 284–292 (2001).
   PubMed Web of Science ®Google Scholar
• Giroglou T, Sapp M, Lane C et al. Immunological analyses of human papillomavirus capsids. Vaccine19(13–14), 1783–1793 (2001).
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet367(9518), 1247–1255 (2006).
   PubMed Web of Science ®Google Scholar
• Evans TG, Bonnez W, Rose RC et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J. Infect. Dis.183(10), 1485–1493 (2001).
   PubMed Web of Science ®Google Scholar
• Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med.347(21), 1645–1651 (2002).
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre Phase II efficacy trial. Lancet Oncol.6(5), 271–278 (2005).
   PubMed Web of Science ®Google Scholar
• Mao C, Koutsky LA, Ault KA et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol.107(1), 18–27 (2006).
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet364(9447), 1757–1765 (2004).
   PubMed Web of Science ®Google Scholar
• Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine24(33–34), 5937–5949 (2006).
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Idanpaan-Heikkila I, Lunnas T et al. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy. Int. J. STD AIDS17(4), 237–246 (2006).
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer95(11), 1459–1466 (2006).
   PubMed Web of Science ®Google Scholar
• Viscidi RP, Kotloff KL, Clayman B, Russ K, Shapiro S, Shah KV. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin. Diagn. Lab. Immunol.4(2), 122–126 (1997).
   PubMedGoogle Scholar
• Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med.3(5), E138 (2006).
   PubMed Web of Science ®Google Scholar
• Wright TC, Van Damme P, Schmitt HJ, Meheus A. Chapter 14: HPV vaccine introduction in industrialized countries. Vaccine24(Suppl. 3), S122–S131 (2006).
   Web of Science ®Google Scholar
• Peny JM, Gleizes O, Covilard JP. Financial requirements of immunisation programmes in developing countries: a 2004–2014 perspective. Vaccine23(37), 4610–4618 (2005).
   PubMed Web of Science ®Google Scholar
• Shank-Retzlaff ML, Zhao Q, Anderson C et al. Evaluation of the thermal stability of Gardasil. Hum. Vaccines,2(4), 147–154 (2006).
   PubMed Web of Science ®Google Scholar
• Gambhira R, Gravitt PE, Bossis I, Stern PL, Viscidi RP, Roden RB. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res.66(23), 11120–11124 (2006).
   PubMed Web of Science ®Google Scholar
• Baud D, Ponci F, Bobst M, De Grandi P, Nardelli-Haefliger D. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. J. Virol.78(23), 12901–12909 (2004).
   PubMed Web of Science ®Google Scholar
• Gaydos CA, Gaydos JC. Adenovirus vaccines in the U.S. military. Military Med.160(6), 300–304 (1995).
   PubMed Web of Science ®Google Scholar
• Berg M, Gambhira R, Siracusa M, Hoiczyk E, Roden R, Ketner G. HPV16 L1 capsid protein expressed from viable adenovirus recombinants elicits neutralizing antibody in mice. Vaccine25(17), 3501–3510 (2007).
   PubMedGoogle Scholar
• Varsani A, Williamson AL, Rose RC, Jaffer M, Rybicki EP. Expression of human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi. Arch. Virol.148(9), 1771–1786 (2003).
   PubMed Web of Science ®Google Scholar
• Maclean J, Rybicki EP, Williamson AL. Vaccination strategies for the prevention of cervical cancer. Exp. Rev. Anticancer Ther.5(1), 97–107 (2005).
   PubMed Web of Science ®Google Scholar
• Varsani A, Williamson AL, Stewart D, Rybicki EP. Transient expression of human papillomavirus type 16 L1 protein in Nicotiana benthamiana using an infectious tobamovirus vector. Virus Res.120(1–2), 91–96 (2006).
   PubMed Web of Science ®Google Scholar
• McLean CS, Churcher MJ, Meinke J et al. Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus. J. Clin. Pathol.43(6), 488–492 (1990).
   PubMed Web of Science ®Google Scholar
• Vambutas A, DeVoti J, Nouri M et al. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine23(45), 5271–5280 (2005).
   PubMed Web of Science ®Google Scholar
• DeFilippis RA, Goodwin EC, Wu L, DiMaio D. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J. Virol.77(2), 1551–1563 (2003).
   PubMedGoogle Scholar
• Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nature Rev.2(1), 59–65 (2002).
   Google Scholar
• Borysiewicz LK, Fiander A, Nimako M et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet347(9014), 1523–1527 (1996).
   PubMed Web of Science ®Google Scholar
• Kaufmann AM, Stern PL, Rankin EM et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin. Cancer Res.8(12), 3676–3685 (2002).
   PubMed Web of Science ®Google Scholar
• Muderspach L, Wilczynski S, Roman L et al. A Phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res.6(9), 3406–3416 (2000).
   PubMed Web of Science ®Google Scholar
• Steller MA, Gurski KJ, Murakami M et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin. Cancer Res.4(9), 2103–2109 (1998).
   PubMed Web of Science ®Google Scholar
• de Jong A, O’Neill T, Khan AY et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine20(29–30), 3456–3464 (2002).
   PubMed Web of Science ®Google Scholar
• van der Burg SH, Kwappenberg KM, O’Neill T et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine in homologous and heterologous prime–boost regimens. Vaccine19(27), 3652–3660 (2001).
   PubMed Web of Science ®Google Scholar
• Mendoza L, Bubenik J, Simova J, Jandlova T, Vonka V, Mikyskova R. Prophylactic, therapeutic and anti-metastatic effects of BMDC and DC lines in mice carrying HPV 16-associated tumours. Int. J. Oncol.23(1), 243–247 (2003).
   PubMedGoogle Scholar
• Santin AD, Bellone S, Palmieri M et al. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol. Oncol.100(3), 469–478 (2006).
   PubMed Web of Science ®Google Scholar
• Berumen J, Casas L, Segura E, Amezcua JL, Garcia-Carranca A. Genome amplification of human papillomavirus types 16 and 18 in cervical carcinomas is related to the retention of E1/E2 genes. Int. J. Cancer56(5), 640–645 (1994).
   PubMed Web of Science ®Google Scholar
• Desaintes C, Demeret C, Goyat S, Yaniv M, Thierry F. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J.16(3), 504–514 (1997).
   PubMed Web of Science ®Google Scholar
• Demeret C, Garcia-Carranca A, Thierry F. Transcription-independent triggering of the extrinsic pathway of apoptosis by human papillomavirus 18 E2 protein. Oncogene22(2), 168–175 (2003).
   PubMedGoogle Scholar
• Greenstone HL, Nieland JD, de Visser KE et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl Acad. Sci. USA, 95(4), 1800–1805 (1998).
   PubMed Web of Science ®Google Scholar
• Qian J, Dong Y, Pang YY et al. Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. Int. J. Cancer118(12), 3022–3029 (2006).
   PubMed Web of Science ®Google Scholar
• Ohlschlager P, Pes M, Osen W et al. An improved rearranged human papillomavirus type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine24(15), 2880–2893 (2006).
   PubMed Web of Science ®Google Scholar
• Li Y, Subjeck J, Yang G, Repasky E, Wang XY. Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy. Vaccine24(25), 5360–5370 (2006).
   PubMed Web of Science ®Google Scholar
• Zhao KJ, Cheng H, Zhu KJ et al. Recombined DNA vaccines encoding calreticulin linked to HPV6bE7 enhance immune response and inhibit angiogenic activity in B16 melanoma mouse model expressing HPV 6bE7 antigen. Arch. Dermatol. Res.298(2), 64–72 (2006).
   PubMedGoogle Scholar
• Lasaro MO, Diniz MO, Reyes-Sandoval A, Ertl HC, Ferreira LC. Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1. Microbes Infect.7(15), 1541–1550 (2005).
   PubMedGoogle Scholar
• Cid-Arregui A, Juarez V, zur Hausen H. A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies. J. Virol.77(8), 4928–4937 (2003).
   PubMed Web of Science ®Google Scholar
• Lin CT, Tsai YC, He L et al. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. J. Biomed. Sci.13(4), 481–488 (2006).
   PubMed Web of Science ®Google Scholar
• Rocha-Zavaleta L, Alejandre JE, Garcia-Carranca A. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses. J. Med. Virol.66(1), 86–95 (2002).
   PubMed Web of Science ®Google Scholar
• Muller M, Zhou J, Reed TD et al. Chimeric papillomavirus-like particles. Virology234(1), 93–111 (1997).
   PubMed Web of Science ®Google Scholar
• Schafer K, Muller M, Faath S et al. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int. J. Cancer81(6), 881–888 (1999).
   PubMed Web of Science ®Google Scholar
• Nieland JD, Da Silva DM, Velders MP et al. Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. J. Cell. Biochem.73(2), 145–152 (1999).
   PubMed Web of Science ®Google Scholar
• Da Silva DM, Schiller JT, Kast WM. Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine21(23), 3219–3227 (2003).
   PubMed Web of Science ®Google Scholar
• Plummer M, Franceschi S. Strategies for HPV prevention. Virus Res.89(2), 285–293 (2002).
   PubMed Web of Science ®Google Scholar
• FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med.356(19), 1915–1927 (2007).
   PubMed Web of Science ®Google Scholar
• Oberling C. The Riddle of Cancer. Yale University Press, CT, USA (1952).
   Google Scholar
• Waelsch L. Ubertragungsversuche mit spitzem kondylom. Arch. Dermatol. Syph.124, 625–646 (1917).
   Google Scholar
• Shope RE. Infectious papillomatosis of rabbits. J. Exp. Med.58, 607–624 (1933).
   PubMedGoogle Scholar
• Lutz W. A propos de l’epidermodysplasie verruciforme. Dermatologica92, 30–43 (1946).
   PubMedGoogle Scholar
• Jablonska S, Dabrowski J, Jakubowicz K. Epidermodysplasia verruciformis as a model in studies on the role of papovaviruses in oncogenesis. Cancer Res.32(3), 583–589 (1972).
   PubMed Web of Science ®Google Scholar
• Orth G, Favre M, Croissant O. Characterization of a new type of human papillomavirus that causes skin warts. J. Virol.24(1), 108–120 (1977).
   PubMed Web of Science ®Google Scholar
• Chen EY, Howley PM, Levinson AD, Seeburg PH. The primary structure and genetic organization of the bovine papillomavirus type 1 genome. Nature299(5883), 529–534 (1982).
   PubMed Web of Science ®Google Scholar
• Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc. Natl Acad. Sci. USA80(12), 3812–3815 (1983).
   PubMed Web of Science ®Google Scholar
• Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J.3(5), 1151–1157 (1984).
   PubMed Web of Science ®Google Scholar
• Rose RC, Bonnez W, Reichman RC, Garcea RL. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J. Virol.67(4), 1936–1944 (1993).
   PubMed Web of Science ®Google Scholar
• Jansen KU, Rosolowsky M, Schultz LD et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine13(16), 1509–1514 (1995).
   PubMed Web of Science ®Google Scholar
• Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol.55(4), 244–265 (2002).
   PubMed Web of Science ®Google Scholar
• Markowitz L, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent Human Papillomavirus Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
   Google Scholar